Format

Send to

Choose Destination
Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183.

The biology and management of non-small cell lung cancer.

Author information

1
Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
2
Washington University School of Medicine, St Louis, Missouri, USA.
3
Pfizer, Inc. New York City, New York, USA.

Abstract

Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.

PMID:
29364287
DOI:
10.1038/nature25183
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center